Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125392701 | 12539270 | 1 | I | 20160623 | 20160708 | 20160708 | EXP | US-CIPLA LTD.-2016US08890 | CIPLA | STEVENSON JP, LANGER CJ, SOMER RA, EVANS TL, RAJAGOPALAN K, KRIEGER K, ET AL. PHASE 2 TRIAL OF MAINTENANCE BEVACIZUMAB ALONE AFTER BEVACIZUMAB PLUS PEMETREXED AND CARBOPLATIN IN ADVANCED, NON-SQUAMOUS NON-SMALL CELL LUNG CANCER. CANCER. 2012;1 TO 8 | 0.00 | Y | 0.00000 | 20160708 | OT | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125392701 | 12539270 | 1 | PS | CARBOPLATIN. | CARBOPLATIN | 1 | Intravenous (not otherwise specified) | AUC6 ON DAY 1 IMMEDIATELY AFTER PEMETREXED | 77383 | INFUSION | |||||||||
| 125392701 | 12539270 | 2 | SS | Pemetrexed | PEMETREXED | 1 | Intravenous (not otherwise specified) | 500 MG/M2, ON DAY 1 | 0 | 500 | MG/M**2 | INFUSION | |||||||
| 125392701 | 12539270 | 3 | SS | Bevacizumab | BEVACIZUMAB | 1 | Intravenous (not otherwise specified) | 15 MG/KG, ON DAY 1 IMMEDIATELY AFTER CARBOPLATIN | U | 0 | 15 | MG/KG | INFUSION | ||||||
| 125392701 | 12539270 | 4 | SS | Bevacizumab | BEVACIZUMAB | 1 | 15 MG/KG, EVERY 3 WEEKS | U | 0 | 15 | MG/KG | INFUSION | |||||||
| 125392701 | 12539270 | 5 | C | VITAMIN B12 | CYANOCOBALAMIN | 1 | Unknown | 1000 MG, EVERY 9 WEEKS | U | U | 0 | 1000 | MG | ||||||
| 125392701 | 12539270 | 6 | C | FOLIC ACID. | FOLIC ACID | 1 | Oral | 1 MG, EVERY DAY 1 WEEK BEFORE THE FIRST CYCLE | U | U | 0 | 1 | MG |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 125392701 | 12539270 | 1 | Non-small cell lung cancer |
| 125392701 | 12539270 | 2 | Non-small cell lung cancer |
| 125392701 | 12539270 | 3 | Non-small cell lung cancer |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 125392701 | 12539270 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 125392701 | 12539270 | Proteinuria |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |